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ABSTRACT 
Purpose 
Growth hormone (GH)-producing pituitary adenomas (PAs) in childhood or young adulthood 
are rare, and the details surrounding these tumors remain enigmatic. We present the clinical, 
pathological and genetic features of this disease. 
Methods 
We identified 25 patients aged 20 years or younger with GH-producing PAs who underwent 
surgery between 2003 and 2016 at Toranomon Hospital in Tokyo. We retrospectively 
reviewed the clinical data, treatment outcomes and pathological features of these patients to 
shed light on childhood acromegaly. 
Results 
The cohort comprised 14 male and 11 female patients whose average age at the time of 
surgery was 17.3 years. Germline AIP mutations were present in 5 of 13 patients examined, 
and Carney complex was identified in 2 of 25 patients. The mean maximum tumor diameter 
was 26.7 mm, and total resection assessed during surgery was achieved in 17 patients. Based 
on their respective pathological findings, patients were divided into the following 4 groups: 
sparsely granulated adenomas (5), densely granulated (DG) adenomas (6), plurihormonal 
adenomas (9), and silent subtype 3 (SS3) adenomas (5). During the mean follow-up period of 
50.3 months, complete endocrinological remission was achieved in 14 of 25 patients (56%) 
by surgery alone and in 19 patients (76%) after postoperative adjuvant therapy. 
Conclusions 
GH-producing PAs in young patients are intriguing and difficult to treat due to their distinct 
tumor characteristics, including a lower incidence of the DG subtype and a higher incidence 
of SS3 adenomas and genetic abnormalities. Therefore, multi-modal therapies are essential to 
achieve optimal clinical outcomes. 
 
Key words: growth hormone-producing pituitary adenoma; young; gigantism; clinical 
feature; pathology; acromegaly 
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INTRODUCTION 
Excess secretion of growth hormone (GH) causes acromegaly, which is associated 
with increased morbidity and mortality. Several heterogeneous disorders, such as pituitary 
adenoma (PA), pituitary hyperplasia, excess ectopic GH release from the bronchial carcinoid, 
and ectopic GH secretion from lymphomas, have been reported to cause excessive GH 
secretion [1-3]; furthermore, primary GH hypersecretion from PAs is the most common cause 
of acromegaly. Moreover, excessive GH secretion during childhood before complete 
epiphyseal closure can lead to gigantism. Because GH-producing PAs during childhood or 
young adulthood are rare, the mechanisms are poorly understood. In this study, we reviewed 
young patients with GH-producing PAs who underwent tumor resection at Toranomon 
Hospital (Tokyo, Japan). GH-producing PAs in young patients have been described as 
aggressive [4-6]; however, the aggravating factors of this clinical entity remain unclear. 
Therefore, we studied the clinical, pathological, and genetic features of younger patients with 
GH-producing PAs to identify factors that exacerbate this clinical condition. 
 
METHODS 
 
Patients 
We retrospectively reviewed the data of 25 patients with GH-producing PA who were 
20 years old or younger at the time of operation. All patients underwent surgery at 
Toranomon Hospital between 2003 and 2016, and a diagnosis of GH-producing PA was 
confirmed by pathological examination. All patients were native Japanese. The mean follow-
up period was 50.3 months (range 1-166). Tumor samples were evaluated upon approval 
from the institutional review boards at Toranomon Hospital and Tokushima University. 
 
Imaging studies 
All patients underwent preoperative contrast-enhanced magnetic resonance imaging 
(MRI). The Knosp classification was assessed using coronal images to determine lateral 
tumor extension, and the maximum tumor diameter was also measured in all patients. The 
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degree of tumor resection was assessed during surgery and was confirmed by postoperative 
MRI, which was generally performed a few days after surgery. Repeated MRI was performed 
several months later when it was difficult to evaluate the tumor excision rate via 
postoperative MRI. Patients with residual tumors underwent postoperative MRI once or twice 
per year to assess tumor regrowth. 
 
Endocrinological evaluations 
Endocrinological examinations were performed in all patients by assessing the serum 
levels of GH and insulin-like growth factor-1 (IGF-1) preoperatively, at postoperative week 1 
and twice per year thereafter. GH levels were measured with a fluorescent enzyme 
immunoassay (ST AIA-PACK HGH, Tosoh Co., Tokyo, Japan). Serum IGF-1 levels were 
measured using an immunoradiometric method (IGF1 IRMA Daiichi, TFB Co., Tokyo, 
Japan). Responses to medical therapy were assessed preoperatively using the octreotide and 
bromocriptine tests, whereas postoperative biochemical remission was defined as a nadir 
serum GH level of <0.4 ng/ml after an oral 75 g glucose load and subsequent normal IGF-1 
levels adjusted for sex and age. For patients receiving postoperative medication or 
radiotherapy (RT), biochemical control at the last follow-up was defined as subsequent 
normal sex- and age-adjusted IGF-1 levels. 
 
Treatments 
Preoperative medication (typically one to three doses of a long-acting somatostatin 
analog (SSA)) was routinely administered to all the patients except those with 
microadenomas. All 25 patients underwent surgical treatment. Most PAs were resected via 
conventional transsphenoidal surgery (TSS), which was performed via an operating 
microscope between 2003 and 2012 and via a neuroendoscope between 2013 and 2016. 
Extended TSS (eTSS) and simultaneous combined TSS and transcranial surgery (TCS) were 
also performed. The details of the surgical strategies used are described in our previous study 
[7]. 
Repeated surgery was performed in patients with residual tumors located in a 
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surgically resectable site. Patients without postoperative endocrinological remission began 
medical therapy. Stereotactic radiotherapy (SRT) was generally implemented when 
endocrinological remission was not achieved using postoperative medication alone and when 
the residual tumor was located in a surgically unresectable location. 
 
Pathological examinations 
Adenoma tissues were evaluated via routine pathological and immunohistochemical 
examinations. Sections were incubated with antibodies targeting the following proteins for 
immunohistochemical evaluation: GH (Dako, Carpinteria, CA, USA; A0570), prolactin 
(PRL) (Dako, Carpinteria, CA, USA; A0569), beta subunit of thyroid-stimulating hormone 
(TSH) (Kyowa Medex Co., Ltd, Tokyo, Japan; AM0335M), adrenocorticotropic hormone 
(ACTH) (Dako, Carpinteria, CA, USA; A0571), follicle-stimulating hormone (FSH) 
(BioGenex, San Ramon, CA, USA; MU026-UC), luteinizing hormone (LH) (Nichirei 
Biosciences Inc., Tokyo, Japan; 412481), cytokeratin (CK) (CAM 5.2) (BD Biosciences, San 
Jose, CA, USA; 345779), Pit-1 (Santa Cruz Biotechnology, TX, USA; sc-393943), Ki67 
(Dako, Carpinteria, CA, USA; M7240) and type 1-alpha regulatory subunit of protein kinase 
A (PRKAR1A) (BD Biosciences, San Jose, CA, USA; 61010). 
Electron microscopy was used for a final diagnosis when we could not reach a final 
morphological diagnosis by a conventional histological examination alone. 
 
Genetic analysis 
Genetic analysis for AIP mutations was performed in 13 of 25 patients. The details 
regarding the genetic analysis of AIP and PRKAR1A mutations have been described in our 
previous studies [8, 9]. Briefly, genomic DNA isolated from leukocytes and PA tissue was 
subjected to 30 cycles of polymerase chain reaction (PCR), the products of which were 
directly sequenced. 
 
Statistical analysis 
Statistical analyses were performed using the Chi square test and the Mann-Whitney 
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U test. Differences of p<0.05 were considered statistically significant. 
 
RESULTS 
Twenty-five patients with GH-producing PA who were 20 years old or younger 
accounted for 2.1% of the 1205 acromegalic patients who underwent surgical treatment for 
PA at Toranomon Hospital during the same period. These 25 patients comprised 14 males and 
11 females with a mean age of 17.3 years (range 7-20 years). Only 3 patients (12%) were 
younger than 15 years old. Four patients had recurrent disease and had undergone initial 
tumor resection at other hospitals. Regarding clinical manifestations, gigantism (height taller 
than +2S.D. of the mean sex- and age-adjusted height) was detected in 13 patients (52%), and 
acromegalic features were confirmed in 22 patients (88%). The preoperative endocrinological 
tests showed that octreotide successfully suppressed the GH levels (>50%) in 14 patients and 
that bromocriptine suppressed the GH levels in 14 of 18 patients examined. 
 
Tumor characteristics 
The tumors consisted of 4 microadenomas (<10 mm maximum tumor diameter), 18 
macroadenomas (10-40 mm), and 3 giant adenomas (>40 mm); the overall mean maximum 
tumor diameter was 26.7 mm (range 7.5-82 mm). Eight adenomas (32%) were either grade 3 
or 4 on the Knosp classification scale. The tumor characteristics of all the patients are shown 
in Table 1. 
 
Treatments 
Data regarding preoperative medical therapy were available for 23 patients. Fifteen 
patients underwent preoperative medication, whereas the remaining 8 patients did not. 
Among the preoperative medication cohort, 11 patients were administered octreotide, one 
patient lanreotide, one patient cabergoline, one patient lanreotide and cabergoline, and one 
patient an unknown SSA. 
All patients underwent surgical treatment(s) as follows: conventional TSS (20), 
extended TSS (2), or simultaneous combined TSS and TCS (3). Gross total tumor resection 
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(GTR) was achieved in 17 of 25 cases (68%); among the 8 patients without GTR, 3 
underwent secondary TSS, one of whom achieved GTR. Fourteen patients (56%) achieved 
endocrinological remission after surgery alone, and none of these patients have shown 
endocrinological relapse during the mean follow-up period of 29.5 months (range from 1 to 
166 months). 
After surgery, 9 patients with residual tumors or without endocrinological complete 
remission received postoperative adjuvant therapy, 7 received medical therapy, and 6 received 
SRT. At the time of last follow-up, endocrinological control was achieved in 19 patients 
(76%). These treatment outcomes are summarized in Table 1. 
 
Pathology 
Based on their pathological findings, 5 adenomas were classified as sparsely 
granulated (SG) subtype, 6 adenomas as densely granulated (DG) subtype, 9 adenomas as 
plurihormonal (PH) subtype (including 6 mammosomatotroph adenomas, 2 acidophil stem 
cell adenomas, and 1 mixed GH-PRL adenoma), and 5 adenomas as silent subtype 3 (SS3) 
adenoma. Patients with DG adenomas presented the highest preoperative serum GH and IGF-
1 levels. The endocrinological remission rate of patients with SG adenomas was lower than 
that of patients with DG adenomas, although those with SG adenomas showed lower Knosp 
grades and a higher rate of GTR. In contrast, SS3 adenomas showed the largest mean 
maximum tumor diameter (43.2 mm, range 23.5-82 mm) and the highest cavernous sinus 
(CS) invasion rate (60%); thus, none of the 5 patients with SS3 adenomas achieved GTR. The 
mean Ki67 labeling index of the SS3 adenomas (3.36%, range 0.2-12%) was the highest 
among these pathological groups. PH adenomas showed the smallest mean tumor size (14.5 
mm, range 7.5-23.8 mm) with a low frequency of CS invasion (11.1%), and GTR was 
achieved in all patients with PH adenomas. The tumor characteristics and clinical outcomes 
of each pathological group are summarized in Table 2. 
 
Genetic anomalies 
In this patient cohort, there were 5 patients with a germline AIP mutation and 2 
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patients with a germline mutation in PRKAR1A, which is the gene responsible for Carney 
complex. Both gigantism and acromegalic features were observed in these 7 patients, and the 
mean maximum tumor diameter of patients with an AIP mutation was 28.9 mm (range 23.8-
36.4). Three of the 5 patients achieved GTR. Two patients achieved endocrinological 
remission by surgery alone, and 3 patients achieved endocrinological control at the last 
follow-up. Moreover, isolated familial somatotropinoma was found in one patient with an 
AIP mutation. 
In contrast to the characteristics of patients with an AIP mutation, the mean maximum 
tumor diameter of patients with Carney complex was 14.7 mm (9.9 and 19.5 mm), but 
endocrinological remission was obtained neither by surgery alone nor by surgery with 
postoperative adjuvant therapy despite these 2 patients achieving GTR. 
 
DISCUSSION 
GH-producing PAs in young patients is a rare clinical condition; only 2.1% of the 
1205 patients with GH-producing PAs admitted to Toranomon Hospital were considered 
young patients. Therefore, the details of this intriguing clinical condition within this 
subpopulation remain unclear. In this article, we reviewed the characteristics of a 
considerable number of young patients with GH-producing PAs who underwent surgery. The 
overall surgical remission rate of young patients (56%) was significantly lower than that of 
our previous series, including acromegalic patients of all ages (84.7%, p=0.002) [7]. 
Although the clinical aggressiveness of GH-producing PAs in young patients has been 
reported [4-6], we assessed the factors that contributed to this poor therapeutic outcome in 
our cohort of young patients. 
 
Tumor factors 
Previous surgical series of patients with GH-producing PAs have shown that the mean 
maximum tumor diameter ranges from 17.4 to 19.4 mm; however, our cohort presented with 
larger mean tumor diameters (26.7 mm) than the tumors in those series [10-12]. The tumor 
sizes of the 25 adenomas in this study were significantly larger than those in our previous 
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study, which included 150 GH-producing PAs (17.8 mm, p=0.001) [7]. Moreover, 8 of the 25 
patients (32%) in our cohort had PAs with Knosp grades 3 and 4; this ratio is higher than 
those described in previous reports (17.3-27.4%) [7, 11, 12]. A high rate of CS invasion of 
GH-producing PAs in young patients has also been reported in the literature [6]. Several 
studies have shown that surgical remission is less likely to be achieved in patients with larger 
tumors or with CS invasion [7, 13, 14]. Thus, the tumor characteristics, such as larger tumor 
size and a higher frequency of CS invasion, observed in these 25 young patients with GH-
producing PAs could be exacerbating factors of this clinical condition. 
 
Pathological factors 
Surgical outcomes are usually better in patients with DG adenomas than in those with 
SG adenomas [15, 16]. DG adenomas accounted for 24% of the cases in this study, which 
appeared to be markedly lower than the rate reported in previous studies by our group and 
others [17-19]. This rate may be another contributing factor for the poor surgical outcomes 
observed in the present study. Interestingly, in this study, patients with DG adenomas 
presented a higher Knosp grade and a lower GTR rate than those with SG adenomas. 
However, the overall endocrinological control rate of DG adenomas was higher than that of 
SG adenomas. It is plausible that the increased responsiveness of DG adenomas to SSA 
treatment, which has been reported in other studies [15, 20-23], could improve the overall 
remission rate of DG adenomas in this series. On the other hand, SS3 adenomas, which were 
originally proposed as a variant of silent corticotroph adenomas [24], are now considered a 
distinct and aggressive histologic variant of PA that are positive for the pituitary-specific 
transcription factor Pit-1 [25-31]. SS3 adenomas have been termed “silent”, whereas some 
SS3 adenomas were reported to be associated with conditions indicative of hormonal excess, 
including acromegaly [27, 29]. In this study, SS3 adenomas showed radiologically and 
pathologically aggressive features, including the largest mean tumor diameter, the highest CS 
invasion rate and the highest mean Ki67 labeling index. In addition, 5 of 25 patients (20%) 
were diagnosed with this type, which indicates a higher incidence of SS3 adenomas among a 
younger population than that stated in previous reports [28]. According to the literature, SS3 
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adenomas are estimated to encompass approximately 1.5% of all PAs. The higher incidence 
of SS3 adenomas might be another aggravating factor of poor surgical outcomes in the 
present study. However, 4 of 5 patients with SS3 adenoma eventually achieved 
endocrinological control at the last follow-up. Some SS3 adenomas have also been reported 
to potentially respond well to SSAs and RT [31]. However, close follow-up is needed in 
patients with SS3 adenomas because higher recurrence rates of SS3 adenomas have also been 
reported [27-29]. 
PH adenomas presented the smallest tumor size and the lowest Knosp grade in this 
series. All these patients achieved GTR, and the endocrinological remission rate was 
favorable. In some articles, mammosomatotroph adenoma showed an equally good prognosis 
as DG adenomas, whereas acidophil stem cell adenoma and mixed GH/PRL cell adenomas 
exhibited more aggressive behavior [32, 33]. In this series, 6 of 9 patients with PH adenomas 
presented with the mammosomatotroph adenoma subtype. 
 
Genetic factors 
In this series of patients, 7 had GH-producing adenomas due to genetic abnormalities 
(5 with an AIP mutation and 2 with PRKAR1A mutations). The physical manifestations of 
gigantism were observed in these 7 patients, suggesting that disease onset in these patients 
was earlier than in patients without genetic anomalies. In fact, the mean age at operation in 
patients with genetic abnormalities was 15.4 years (range 7-19 years), which is younger than 
that of patients without genetic abnormalities (18 years (range 14-20 years)), although this 
difference is not statistically significant (p=0.07). Moreover, among these 7 patients with 
genetic abnormalities, only 3 (42.9%) achieved endocrinological remission at the last follow-
up. The overall endocrinological control rate in patients with genetic abnormalities was 
statistically lower than that of patients without genetic abnormalities (88.9%, p=0.03). This 
outcome suggests the intractability of GH-producing PAs in patients with genetic 
abnormalities. 
Among the 5 patients with an AIP mutation, all presented with large macroadenomas 
(28.9 mm of mean maximum tumor diameter), and 1 patient showed CS invasion. 
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Endocrinological control was achieved in 3 of the 5 patients at the time of last follow-up. 
Daly et al. reported that somatotropinomas with an AIP mutation tend to be larger in size and 
have a worse disease control rate over a long-term period [34]. AIP mutations have been 
reported to be an unfavorable factor for the SSA treatment response in patients with 
acromegaly [34]. Consistent with other reports, poor outcomes in patients with an AIP 
mutation were also noted in our series. Vierimaa et al. reported that 40% of patients with GH-
producing PAs diagnosed when they were younger than 35 years of age had AIP mutations 
[35]. The proportion of AIP mutation in our study (5/13, 38.5%) seemed to be equivalent to 
the ratio. However, the number of samples was too small to reach a definitive conclusion 
(genetic analyses of AIP mutations were performed in only 13 patients in this series). 
Moreover, our cohort included only 1 patient with familial isolated pituitary adenoma 
(isolated familial somatotropinoma) with an AIP mutation. 
Neither of the 2 patients with Carney complex achieved endocrinological control by 
the last follow-up, although they both presented with small maximum tumor diameters (9.9 
and 19.5 mm) and lower Knosp grades (grade 0 and 2, respectively). PAs due to Carney 
complex are reported to have multiple tiny tumor nodules in addition to an isolated primary 
tumor mass [36, 37]. Watson et al. described a patient with Carney complex in which the 
microadenoma was not detected on preoperative MRI [38]. Similarly, small scattered islands 
of adenoma cells were detected within the adjacent normal pituitary in patients in the present 
study (Figure 1). This finding could be a major contributor to the failure to achieve surgical 
remission in patients with Carney complex. 
 
Multi-modal therapy 
Among the patients within our cohort, the surgical remission rate was 56%, whereas 
the endocrinological control rate at the last follow-up increased to 76%. Several studies have 
demonstrated that GH-producing PAs in young patients cannot be adequately controlled by 
surgery alone and that a combination of medical therapy and/or RT is necessary [4, 5]. In our 
series, most patients exhibited sufficient GH suppression in the preoperative octreotide and 
bromocriptine tests. Five of 11 patients who failed to achieve surgical remission eventually 
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attained endocrinological control with postoperative adjuvant therapy. Thus, multi-modal 
therapies, such as surgical resection combined with medical treatment and/or RT, are essential 
to achieve an optimal clinical outcome for young individuals with difficult-to-treat GH-
producing adenomas. 
 
CONCLUSIONS 
GH-producing PAs in childhood or young adulthood are rare but intriguing and 
difficult to treat due to their distinct tumor characteristics (including large tumor size with 
frequent CS invasion), a lower incidence of the DG subtype, a higher incidence of SS3 
adenoma, and genetic abnormalities (in some patients). The overall surgical remission rate 
tends to be lower in these patients than in adults; thus, multi-modal therapies must be 
considered to achieve optimal clinical outcomes. 
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FIGURE CAPTION 
Fig. 1 Pathology of a normal pituitary gland in a patient with Carney complex (patient 18 in 
Table 1). a A small island of tumor cells (black circle) was detected in the normal pituitary 
anterior lobe using Hematoxylin-eosin staining. b The tumor mass was detected as the 
immunonegative area (red circle) using anti-PRKAR1A staining, which indicates that the 
tumor etiology is Carney complex 
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Table 2. The tumor characteristics and clinical outcomes of each pathological group of 
GH-producing adenomas 
 SG DG PH SS3 
Number of cases (%) 5 (20) 6 (24) 9 (36) 5 (20) 
Preoperative serum GH level (ng/mL) 28.4 150.8 32.2 29.2 
Preoperative serum IGF-1 level (ng/mL) 653 1155 827 811 
Mean maximum tumor diameter (mm) 29.2 29.0 14.5 43.2 
Knosp grade ≥ 3 (N (%)) 1 (20) 3 (50) 1 (11.1) 3 (60) 
Mean Ki67 labeling index (%) 1.82 0.82 3.26 3.36 
GTR (N (%)) 4 (80) 4 (66.7) 9 (100) 0 (0) 
Endocrinological remission by surgery 
alone (N (%)) 
3 (60) 3 (50) 7 (77.8) 1 (20) 
Overall endocrinological control (N (%)) 3 (60) 5 (83.3) 7 (77.8) 4 (80) 
GTR: gross total resection, SG: sparsely granulated adenoma, DG: densely granulated 
adenoma, PH: plurihormonal adenoma, SS3: silent subtype 3 adenoma 
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 
